Graft characteristics
| Number of patients, N | 233 | |
| Median transplant year (range) | 2009 | (1992-2020) |
| Transplant period, n (%) | ||
| 1988-2000 | 15 | (6%) |
| 2001-2005 | 32 | (14%) |
| 2006-2010 | 110 | (47%) |
| 2011-2015 | 68 | (29%) |
| ≥2016 | 8 | (3%) |
| Graft type, n (%) | ||
| Unrelated UCB | 233 | (100%) |
| Graft source, n (%) | ||
| Single UCB unmanipulated | 147 | (63%) |
| Single UCB expanded | 2 | (1%) |
| Double UCB | 77 | (33%) |
| Intrabone injection of 1 of the UCB | 7 | (3%) |
| HLA mismatch, n (%) | ||
| 0-1/6 | 109 | (47%) |
| 2/6 | 90 | (39%) |
| 3/6 | 7 | (3%) |
| Missing | 27 | (11%) |
| Cell dose, median (IQR) | ||
| Median TNC at cryopreservation (×107/kg) | 4.7 | (3.6-6.3) |
| Median CD34+ cell at cryopreservation (×105/kg) | 1.9 | (1.3-3.1) |
| Number of patients, N | 233 | |
| Median transplant year (range) | 2009 | (1992-2020) |
| Transplant period, n (%) | ||
| 1988-2000 | 15 | (6%) |
| 2001-2005 | 32 | (14%) |
| 2006-2010 | 110 | (47%) |
| 2011-2015 | 68 | (29%) |
| ≥2016 | 8 | (3%) |
| Graft type, n (%) | ||
| Unrelated UCB | 233 | (100%) |
| Graft source, n (%) | ||
| Single UCB unmanipulated | 147 | (63%) |
| Single UCB expanded | 2 | (1%) |
| Double UCB | 77 | (33%) |
| Intrabone injection of 1 of the UCB | 7 | (3%) |
| HLA mismatch, n (%) | ||
| 0-1/6 | 109 | (47%) |
| 2/6 | 90 | (39%) |
| 3/6 | 7 | (3%) |
| Missing | 27 | (11%) |
| Cell dose, median (IQR) | ||
| Median TNC at cryopreservation (×107/kg) | 4.7 | (3.6-6.3) |
| Median CD34+ cell at cryopreservation (×105/kg) | 1.9 | (1.3-3.1) |
TNC, total nucleated cells.